Evidence map›Paper›PMID 39614705›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

High-Resolution Molecular-Dynamics Simulations of the Pyruvate Kinase Muscle Isoform 1 and 2 (PKM1/2).

Quentin Delobelle, Théo Jaffrelot Inizan, Olivier Adjoua, Louis Lagardère, Frédéric Célerse, Vincent Maréchal, Jean-Philip Piquemal

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Isoform-specific regulation of PKM by acetylation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Quentin DelobelleCentre de Recherche Saint-Antoine - Team "Biologie et Thérapeutique du Cancer", UMRS 938 INSERM, Paris, France.
Théo Jaffrelot InizanSorbonne Université, CNRS, Laboratoire de Chimie Théorique, UMR 7616, 75005, Paris, France.
Olivier AdjouaSorbonne Université, CNRS, Laboratoire de Chimie Théorique, UMR 7616, 75005, Paris, France.
Louis LagardèreSorbonne Université, CNRS, Laboratoire de Chimie Théorique, UMR 7616, 75005, Paris, France.
Frédéric CélerseSorbonne Université, CNRS, Laboratoire de Chimie Théorique, UMR 7616, 75005, Paris, France.
Vincent MaréchalCentre de Recherche Saint-Antoine - Team "Biologie et Thérapeutique du Cancer", UMRS 938 INSERM, Paris, France.
Jean-Philip PiquemalSorbonne Université, CNRS, Laboratoire de Chimie Théorique, UMR 7616, 75005, Paris, France.ORCID https://orcid.org/0000-0001-6615-9426

Funding

H2020 European Research Council 810367
6 · The paper itself

Abstract

Glucose metabolism plays a pivotal role in physiological processes and cancer growth. The final stage of glycolysis, converting phosphoenolpyruvate (PEP) into pyruvate, is catalyzed by the pyruvate kinase (PK) enzyme. Whereas PKM1 is mainly expressed in cells with high energy requirements, PKM2 is preferentially expressed in proliferating cells, including tumor cells. Structural analysis of PKM1 and PKM2 is essential to design new molecules with antitumoral activity. To understand their structural dynamics, we performed extensive high-resolution molecular dynamics (MD) simulations using adaptive sampling techniques coupled to the polarizable AMOEBA force field. Performing more than 6 μs of simulation, we considered all oligomerization states of PKM2 and propose structural insights for PKM1 to further study the PKM2-specific allostery. We focused on key sites including the active site and the natural substrate Fructose Bi-Phosphate (FBP) fixation pocket. Additionally, we present the first MD simulation of biologically active PKM1 and uncover important similarities with its PKM2 counterpart bound to FBP. We also analysed TEPP-46's fixation, a pharmacological activator binding a different pocket, on PKM2 and highlighted the structural differences and similarities compared to PKM2 bound to FBP. Finally, we determined potential new cryptic pockets specific to PKM2 for drug targeting.

Indexed as

Carrier ProteinsMembrane ProteinsPyruvate KinaseThyroid HormonesAllosteric RegulationCatalytic DomainGlycolysisHumansMolecular Dynamics SimulationProtein BindingThyroid Hormone-Binding ProteinsCarrier ProteinsMembrane ProteinsPyruvate KinaseThyroid Hormone-Binding ProteinsThyroid Hormonesadaptive samplingAMOEBA polarizable force fieldcancerchemistrymolecular dynamicspyruvate kinase

Identifiers

PMID39614705
PMCPMC11973853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.